Takeda, Japan's biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of alogliptin or SYR-322, which is critical to Takeda's mainstay diabetes business as it is expected to be the main replacement for its best-selling Actos.
Actos generates almost 30 percent of Takeda's sales but loses U.S. patent protection in 2011.
More
Showing posts with label alogliptin. Show all posts
Showing posts with label alogliptin. Show all posts
Friday, October 10, 2008
Subscribe to:
Posts (Atom)